West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$315.20 USD
-2.49 (-0.78%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $315.15 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
WST 315.20 -2.49(-0.78%)
Will WST be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for WST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WST
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
WST: What are Zacks experts saying now?
Zacks Private Portfolio Services
West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
Will West Pharmaceutical (WST) Beat Estimates Again in Its Next Earnings Report?
Other News for WST
West Pharmaceutical Services Inc. stock underperforms Wednesday when compared to competitors
Sell ideas in Staples and Health Care - Oppenheimer
West Introduces Daikyo Crystal Zenith® (CZ) Ready-to-Use Nested Vials in Tub at the International Society for Cell and Gene Therapy
10 Dividend Growth Stocks: May 2024
West to Participate in Upcoming Investor Conference